secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062042
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics Q3 net loss $20.8M; cash $263.5M; ELVN-001/002 data on track for 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $263.5M as of Sept 30, 2023; expected runway into early 2026.
- Net loss $20.8M vs $10.6M in Q3 2022; R&D expense $19.6M (up from $7.8M); G&A $4.6M (up from $3.1M).
- ELVN-001 (CML) and ELVN-002 (HER2-altered solid tumors) Phase 1 trials enrolling; initial proof-of-concept data expected in 2024.
- Third IND-enabling study completed; additional pipeline details and guidance planned for H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000095017023062042/0000950170-23-062042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000095017023062042/elvn-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer